CUS Stock Overview

A biotech company, develops treatment of cancer. More details

CUS fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 105.6% per year

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 44.9% per year over past 5 years

Makes less than USD$1m in revenue (DKK0)

Shares are highly illiquid

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Curasight A/S Competitors

Medigene

XTRA:MDG1

€22.3m

4SC

DB:VSC

€61.3m

2invest

XTRA:2INV

€67.8m

co.don

XTRA:CNW

€6.5m

Price History & Performance

Summary of share price highs, lows and changes for Curasight
Historical stock prices
Current Share Price	DKK 1.10
52 Week High	DKK 1.23
52 Week Low	DKK 1.10
Beta	0.15
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.20%

Recent updates

Shareholder Returns

	CUS	DE Biotechs	DE Market
7D	-10.2%	1.1%	-0.02%
1Y	n/a	-3.7%	15.1%

Return vs Industry: Insufficient data to determine how CUS performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how CUS performed against the German Market.

Price Volatility

Is CUS's price volatile compared to industry and market?
CUS volatility
CUS Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CUS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine CUS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	4	Ulrich Krasilnikoff	www.curasight.com

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue.

Curasight A/S Fundamentals Summary

How do Curasight's earnings and revenue compare to its market cap?
CUS fundamental statistics
Market cap	€26.25m
Earnings (TTM)	-€4.33m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-6.1x

P/E Ratio

Is CUS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CUS income statement (TTM)
Revenue	DKK 0
Cost of Revenue	DKK 28.01m
Gross Profit	-DKK 28.01m
Other Expenses	DKK 4.28m
Earnings	-DKK 32.29m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	-1.53
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	78.2%

How did CUS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 23:53
End of Day Share Price	2025/02/07 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Curasight A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Fredrik Thor	Redeye

Curasight DB:CUS Stock Report